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Abstract
Intratumour heterogeneity (ITH) may foster tumour adaptation and compromise the efficacy of personalized
medicine approaches. The scale of heterogeneity within a tumour (intratumour heterogeneity) relative to genetic
differences between tumours (intertumour heterogeneity) is unknown. To address this, we obtained 48 biopsies
from eight stage III and IV clear cell renal cell carcinomas (ccRCCs) and used DNA copy-number analyses to
compare biopsies from the same tumour with 440 single tumour biopsies from the Cancer Genome Atlas (TCGA).
Unsupervised hierarchical clustering of TCGA and multi-region ccRCC samples revealed segregation of samples
from the same tumour into unrelated clusters; 25% of multi-region samples appeared more similar to unrelated
samples than to any other sample originating from the same tumour. We found that the majority of recurrent
DNA copy number driver aberrations in single biopsies were not present ubiquitously in late-stage ccRCCs and
were likely to represent subclonal events acquired during tumour progression. Such heterogeneous subclonal
genetic alterations within individual tumours may impair the identification of robust ccRCC molecular subtypes
classified by distinct copy number alterations and clinical outcomes. The co-existence of distinct subclonal copy
number events in different regions of individual tumours reflects the diversification of individual ccRCCs through
multiple evolutionary routes and may contribute to tumour sampling bias and impact upon tumour progression
and clinical outcome.
 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Over the last 5 years, tumour deep sequencing
studies have revealed the scale of diversity between
tumours (intertumour heterogeneity), with few somatic
alterations shared between tumours of the same
histopathological subtype [1–5]. Increasingly, evi-
dence is emerging of extensive variation within
individual tumours, termed ’intratumour heterogene-
ity’, with reports of diversity in DNA ploidy, somatic
mutation and DNA copy number status in both
haematological and solid tumours [6–15].
Morphological intratumour heterogeneity has been
recognized for several decades and forms the basis of
many pathological grading tools, where variation in
nuclear size (nuclear pleomorphism), a poor prognostic
marker, provides an estimate of diversity between cells
of the same tumour [16]. Furthermore, mechanisms
generating genetic diversity within tumours, such as
chromosomal instability, are associated with poor
patient prognosis [17–21].
 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland.
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Diversity within individual tumours may contribute
to the acquisition of drug resistance or progres-
sion to invasive disease by facilitating subclonal
selection [22]. This has been witnessed in lung
cancer treatment; patients on epidermal growth factor
receptor tyrosine kinase inhibitors have a poorer
progression-free survival if the tumour harbours a
low-frequency gatekeeper resistance mutation, T790M,
prior to therapy initiation [23]. Clonal diversity is
also associated with increased risk of progression
from premalignant Barrett’s oesophagus to inva-
sive oesophageal adenocarcinoma [21]. Intratumour
heterogeneity may also confound efforts to predict
long-term outcome and personalize cancer medicine,
if treatment-resistant tumour subclones are only
present at low frequency and evade detection at first
presentation [24]. Somatic mutational heterogeneity
has also been shown to result in heterogeneous signal
transduction pathway dependencies [15]. Such diver-
sity may impact upon stratified medicine approaches,
where the entire somatic mutational landscape of the
tumour is not represented by a single tumour biopsy,
and transcriptomic signatures of outcome vary between
good and poor outcome within a primary tumour.
Due to this scale of heterogeneity, ubiquitous ’tumour
trunk’ driver events present in multiple regions of a
tumour may prove more effective therapeutic targets
than heterogeneous ’tumour branch’ events, that may
evade detection in a single biopsy [25].
Despite these observations of intratumour genetic,
transcriptomic and phenotypic variation from biopsy to
biopsy, the scale of intratumour genetic heterogeneity
relative to diversity between tumours of the same
histopathological subtype in advanced metastatic
tumours remains unclear. Minimal intratumour
genomic variation relative to the scale of diversity
between patients might suggest a more modest impact
of intratumour heterogeneity on personalized medicine
approaches derived from single tumour biopsies. In
contrast, if the scale of genomic change between
biopsies from the same tumour can, in some cases,
tend toward a similar magnitude as the variation
between tumours from different patients, this might
suggest a greater challenge to biomarker discovery
and validation initiatives.
We applied SNP array analysis to multiple biop-
sies from each of eight clear cell renal carcinomas
(ccRCCs) and compared the copy number profiles to
those occurring in tumours of the same histopatho-
logical subtype. We found that the scale of genetic
heterogeneity within individual tumours mimicked
diversity between tumours of the same histopatho-
logical subtype. The observation that multiple copy
number profiles can co-exist within individual tumours
indicates that discrete and uniform copy number-
defined ccRCC subgroups may not exist in advanced
disease. We conclude that intratumour diversity in
copy number states, together with somatic mutational
heterogeneity, provide multiple parallel routes for
tumour progression and metastasis.
Materials and methods
Patient samples and consent
Samples from patients P5, P6 and P7 were col-
lected from nephrectomy specimens acquired
from patients on the E-PREDICT translational
clinical trial (EUDRACT No. 2009-013381-54;
http://public.ukcrn.org.uk/Search/StudyDetail.aspx?
StudyID= 10710, open to recruitment since Jan-
uary 2010; Principal Investigator JL) of pre- and
post-nephrectomy Everolimus treatment in patients
presenting with metastatic renal cell carcinoma,
the details of which were previously reported [15].
Tumours from patients RK21, RK23, RK29, RMH3
and RMH8 were also collected at the Royal Marsden
Hospital, London, but not as part of the PREDICT
trial, and received no therapeutic treatment prior
to nephrectomy. The study and the translational
work were approved by the Royal Marsden Hospital
Research Ethics Committee. The eight patients whose
data are presented gave written informed consent for
study participation and for the translational analyses.
Samples from patient 5 were processed on Affymetrix
SNP6 arrays in a first batch, samples from patients 6
and 7 in a second and all samples from the remaining
five patients in a third batch. Data were deposited in the
GEO database (GSE47077). Affymetrix SNP6 arrays
for 450 ccRCC patients were obtained from TCGA
(https://tcga-data.nci.nih.gov/tcga/) on 14 March 2012.
SNP array data normalization and copy number data
The aroma R package (CRMA v2, CalMaTe ‘v1’
algorithm and TumourBoost) [26–28] was used to
obtain logR and BAF values from the 450 TCGA
tumour samples, using normal samples as references
and hg19 coordinates. logR and BAF values for 63
tumour samples from the eight patients were obtained
with the same method, using a normal sample from
each of the eight patients and all normal TCGA sam-
ples as references. Sex chromosomes were excluded
from the analysis. ASCAT was run on all samples
to obtain copy number profiles and ploidy using
paired normal samples [29]. The output was fur-
ther filtered by selecting segments consisting of more
than 10 probes. Copy number profiling failed for
eight samples (P6-R12, P6-R2, P6-R3, P6-R5, RK21-
R2, RMH3-R1, RMH3-R4, RMH8-R7) and sample
P6-R1 was excluded because of no discernible tumour
content, leaving 54 valid copy number profiles. Cyto-
band coordinates were retrieved from the UCSC
Genome Browser database (http://genome.ucsc.edu/)
[30]. Differences in tumour content can potentially
account for uneven detection of ubiquitous aberra-
tions across related samples. Samples with very low
variability (wGII< 0.01; see below) were thus dis-
carded to avoid undetected normal contamination and
ensure minimum variability for the computation of
sample–sample correlations. Samples P7-R5, P7-R7,
 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2013; 230: 356–364
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P7-R15, RK29-R2, RMH8-R1 and RMH8-R3 and 10
TCGA samples were thus discarded, leaving a total
of 48 multi-region and 440 TCGA samples. Samples
were represented as vectors of the mean copy number
within each cytoband. Loss and gains were defined as
copy numbers deviating from the ploidy, as estimated
by ASCAT, by more than 0.6, similarly to the original
ASCAT publication [29].
Weighted Genomic Instability Index (wGII)
The wGII score [31] is computed on each chromosome
as the proportion of bases whose copy number deviates
from the ploidy value of the sample given by ASCAT
by more than 0.6. The sample score is the sum of the
chromosomal scores divided by the number of analysed
chromosomes (n= 22).
Unsupervised clustering of samples
The pvclust R package [32] was used to cluster
the 48 multi-region and 440 TCGA samples having
passed all quality control checks, using a Spearman
correlation coefficient-based distance, D , such that
Dab= [1—SCC(a , b)]/2 where SCC(a ,b) is the Spear-
man’s rank correlation coefficient between samples a
and b. Dab= 0 if a and b are perfectly correlated;
Dab= 0.5 if the correlation is null; and Dab= 1 if
the samples are perfectly anticorrelated. The number of
bootstrap replications was set to 1000. Significant clus-
ters were identified using a confidence level of 0.05.
A second method was applied by running the hmm-
Mix software [33] to identify three clusters with default
parameters. Integer copy numbers were converted to
log2(copy number/ploidy) values for each cytoband as
input for hmmMix. The operation was repeated to pro-
duce any number from three to 10 clusters.
Network analysis
The cytoscape software [34] was used to produce a
graph view of the fully interconnected network of
multi-region and stage III-IV TCGA samples. Nodes
represent samples and a force-directed layout was
applied using 1—normalized (D) as the force between
them, using a default spring length of 200. Significant
edges were determined as those connecting samples
for which D , the Spearman correlation-based distance
between them, was significantly smaller than expected,
using all pairwise Ds between stage III and IV TCGA
samples as background distribution (p< 0.05, one-
tailed test).
Results
Intratumour heterogeneity in copy number profiles
Cytoband-based copy number profiles were derived
from Affymetrix SNP 6 array analysis for biopsies from
48 regions of eight individual tumours and 440 TCGA
samples. The 488 profiles were then summarized
into a matrix of average copy-number per cytoband.
Three of the multi-region sampled tumours received
Everolimus treatment (P5, P6, P7), while the other five
(RK21, RK23, RK29, RMH3, RMH8) were untreated.
The clinicopathological features of each patient are
described in Table S1 (see Supplementary material).
All regions in all multi-region sampled tumours, except
those from patient RK21, displayed loss of genomic
material on chromosome 3p (Figure 1). However,
all four samples from patient RK21 displayed loss
of heterozygosity on the entire chromosome 3 (see
Supplementary material, Figure S1). Variability was
observed amongst profiles from each individual patient,
indicating the presence of ITH of chromosomal gains
and losses in all analysed ccRCCs. For instance, patient
RK29 displayed two distinct subclonal populations
defined by events observed only in a fraction of
all RK29 samples; nine profiles showed losses on
chromosome 9 and 14q (regions R1, R4, R6, R7, R8,
R10, R11, R12, R13), while three profiles did not
(regions R3, R5 and R9). Patient P5 appeared relatively
homogeneous, with regions R4 (9q loss) R6 (16q loss)
and R2 (5q gain, loss of 6q, 9q and 14q) displaying
additional broad copy number alterations compared to
the other five regions (loss of 3p and 4q).
Hierarchical clustering reveals segregation of copy
number profiles from the same tumour in several
incomplete clusters
The previously generated matrix of average copy num-
ber per cytoband was used to compare DNA copy
number alterations between our 48 biopsies taken from
multiple regions of eight stage III and IV ccRCC
tumours with the 440 single biopsies taken from the
stage I–IV ccRCC cohort from TCGA. Unsupervised
clustering using Spearman’s rank correlation coeffi-
cient was applied to these samples to reveal whether
single tumour biopsies clustered more closely with
biopsies from the same tumour or with biopsies from
other tumours (Figure 2). If biopsies from the same
tumour were more similar to each other than to biop-
sies from different tumours, we would have expected
the emergence of eight robust clusters representing the
biopsies derived from the same patients. One thousand
bootstrapping iterations produced a total of 39 distinct
statistically significant clusters (p< 0.05), consisting of
samples recurrently clustering together throughout the
simulation. Tumour biopsies from patient RK21 were
the only case of the eight tumours analysed in which all
multi-region samples of the same tumour exclusively
and significantly clustered together. Samples from the
same tumour were segregated into two or more clus-
ters in five cases (patients P6, P7, RK23, RK29 and
RMH8) and regions from three of the multi-region
sampled tumours formed significant clusters with at
least one unrelated TCGA sample (patients P5, RK23
and RMH3). This lack of robust tumour-specific clus-
ters suggests that, on a copy-number level, intratumour
 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2013; 230: 356–364
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Figure 1. Copy number profiles of the 48 multi-region samples. Columns represent samples and rows represent cytobands. The colour
coding indicates the relative copy number of each cytoband in each sample (the copy number observed in a cytoband minus the sample’s
ploidy). Sample labels are coloured to identify the patient of origin.
heterogeneity in stage III–IV ccRCCs may result in
DNA copy number profiles that are more similar to
copy number profiles of other tumours, including early-
stage tumours, than to spatially separated biopsies from
the same tumour. Similar results were obtained when
the analysis was restricted to include only the subset of
stage III and IV samples from the TCGA cohort (see
Supplementary material, Figure S2), or using Euclidean
rather than correlation-based distances (see Supple-
mentary material, Figure S3).
We repeated the analysis using a model-based clus-
tering method (hmmMix [33]; see Materials and meth-
ods) to assess whether an independent, non-hierarchical
approach method would produce comparable results.
Analyses in which the algorithm was instructed to
group samples into three to 10 clusters consistently
revealed that spatially separated biopsies from the same
tumour resided in different DNA copy number clusters.
Results are shown for four clusters (see Supplementary
material, Figure S4), in which case five of the eight
multi-region sampled tumours harboured biopsies that
resided in two or more clusters. Only the samples from
patients P6, RMH3 and RMH8 were located in the
same cluster.
Scale of intratumour heterogeneity mimics
intertumour heterogeneity
To further assess how often a given biopsy resembled
an unrelated sample more than any other biopsy from
the same tumour, we identified the copy-number profile
with the shortest sample-to-sample distance to each of
the multi-region sample profiles (see Supplementary
material, Table S2). Depending on the distance metrics
used, at least one sample in up to six of the eight
tumours was more similar to an unrelated sample rather
than to any other sample from the same tumour. In
total, 25% of the 48 biopsies from the eight tumours
appeared to be more similar to an unrelated sample than
to any related sample. This indicates that the similarity
between one or more biopsies from the same tumour
with unrelated samples is observed independently of
clustering methods.
We used a network approach to illustrate how copy
number profiles from the same tumour correlate with
each other and those of unrelated stage III and IV
samples (Figure 3). In this network, nodes repre-
sent samples (diamonds for stage III tumours, cir-
cles for stage IV) and the edges (lines) connecting
them are weighted by the Spearman correlation-based
 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2013; 230: 356–364
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Figure 2. Hierarchical clustering of 440 TCGA samples and 48 multi-region samples from eight patients. Heat map columns represent
samples and are ordered to match the dendrogram, while rows represent cytobands. The hierarchical clustering is based on Spearman’s
rank correlation coefficient between samples. The colour coding indicates the relative copy number of each cytoband in each sample.
Significant clusters obtained using 1000 bootstrapping iterations are highlighted by bars below the copy number profiles of the relevant
samples, using alternating grey and black for clarity. Multi-region samples are highlighted and reported below the significant clusters bar.
distances used for clustering in Figure 2 (see Materials
and methods). Thick lines highlight pairs of samples
with significant similarity to each other, as defined
by a sample-to-sample distance which is smaller than
expected by chance (p< 0.05). In total, 36 of 48
(75%) of the multi-region samples are only signif-
icantly similar to some, but not all, other samples
from their tumour of origin (see Supplementary mate-
rial, Table S3). Of these 36 samples, 28 are also
significantly similar to samples from unrelated high-
stage tumours. Furthermore, one sample (RK23-R4)
is only significantly similar to samples from different
tumours and three samples (P6-R10, P7-R6 and P7-
R9) are not significantly similar to any other sample.
Network representation provides a deeper insight into
the similarities between advanced ccRCC copy num-
ber profiles from common and unrelated origins. For
instance, while the similarities of samples P5-R2 and
P5-R4 with other samples from patient 5 are smaller
than expected by chance, they are more similar and
located closer to TCGA samples. The two subclonal
populations observed in patient RK29 are also identi-
fiable as two separate, highly interconnected groups.
Comparable results were obtained using Euclidean
instead of correlation-based distances (see Supplemen-
tary material, Figure S5). These results suggest that
intratumour heterogeneity in advanced ccRCCs can
result in divergence between subclonal populations of
the same tumour that is on a similar scale to that seen
between different tumours. In addition, such a high
divergence in copy number profiles originating from
the same tumour can be observed in both untreated
and Everolimus-treated samples.
ccRCC frequently altered loci demonstrate ITH
occurring following 3p loss
Copy number gains and losses that are detected fre-
quently in ccRCCs have been suggested to be driver
events as they are recurrently selected [35]. Unsuper-
vised clustering of genome-wide copy number profiles
may favour the detection of complex aberration pat-
terns but may fail to detect ccRCC subgroups that,
from a biological point of view, might be better classi-
fied by such single recurrent genomic events. To assess
this possibility, we identified chromosomal gains or
 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2013; 230: 356–364
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Figure 3. Network representation of relationships between multi-region and stage IV TCGA samples. Samples are represented as nodes
(diamonds for stage III samples, circles for stage IV) and correlation-based distances are used to weight the edges connecting them. The
network is fully interconnected and all edges are used to create the layout. Only edges corresponding to distances significantly smaller than
expected (including the bottom 5% of the unrelated samples distance distribution) are drawn with thick lines. Coloured lines highlight
connections between samples from the same tumour; black lines are used for unrelated samples. White node labels indicate regions from
untreated tumours; black node labels indicate regions from treated tumours.
losses present in at least 20% of samples in the TCGA
cohort. Recurrent chromosomal aberrations in kidney
cancer are usually broad, involving most or the whole
of a chromosome arm [35]. Similarly to a previous
study [36], we defined such broad chromosome arm
aberrations as gains or losses of at least half of the
arm’s cytobands in order to ensure high sensitivity and
specificity (see Supplementary material, Figure S6).
Losses were detected on chromosome arms 3p, 6q,
8p, 9p, 9q and 14q, and gains on 5p, 5q, 7p, 7q and
20q. Analysis of each of these events revealed concor-
dant changes in gene expression in 400 TCGA samples
for which RNA-seq data were also available (see Sup-
plementary material, Figure S7), indicating that copy
number changes likely impact upon gene expression in
these regions of recurrent gain or loss.
Analysis of these recurrent chromosomal aberrations
in the six multi-region sampled cases revealed that
chromosome 3p was the only copy number event ubiq-
uitously lost in all regions of all tumours (Figure 4A),
supporting its known role as an early founder genetic
event, important for tumour initiation. All other recur-
rent chromosomal aberrations were found to be hetero-
geneous in at least two patients. Thus, apart from the
early loss of chromosome 3p, recurrent copy number
changes in advanced ccRCCs in this small cohort were
confined to tumour subclones, as opposed to their ubiq-
uitous alteration in all tumour cells (Figure 4A) [25].
This supports a parallel progression model in which
novel driver events are unlikely to eradicate progen-
itor clones through a selective sweep, contributing
to branched evolution and the polyclonal nature of
ccRCCs.
Next we analysed the frequencies of all aberrations
affecting at least half of a chromosome arm detected
in at least one tumour sample from the multi-region
copy number analysis (Figure 4B).The number of aber-
rations varied greatly both between different tumours
and between samples from the same tumour (see Sup-
plementary material, Table S4). These data suggest
that 38–96% of the large chromosomal aberrations
in an individual tumour are heterogeneous and that,
on average, only 40% of the chromosomal aberrations
in a single tumour biopsy derived from a late-stage
ccRCC will be present ubiquitously across the tumour
mass. Thus, the majority of somatic copy number gains
and losses present in a single ccRCC biopsy, includ-
ing recurrent and potential driver aberrations, were
most likely acquired as subclonal events in tumour
progression.
 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2013; 230: 356–364
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Figure 4. Large aberrations in the TCGA and multi-region samples. Large aberrations involve at least half of the length of a chromosome
arm. (A) Occurrences of recurrent aberrations (observed in at least 20% of the TCGA samples) in the multi-region samples. Samples and
chromosomal aberrations are represented by columns and rows, respectively. Colours differ for each patient. Colours indicate the presence
of an aberration in a sample and white indicates their absence. (B) Frequencies of large aberrations in multi-region samples summarized
for each patient. Aberrations that did not occur in the multi-region samples were not plotted. Darker colours indicate higher frequency
of an aberration in samples from the same patient. (C) Co-occurrences of recurrent large aberrations in TCGA samples. *Regions showing
ubiquitous loss of heterozygosity without overall copy number loss.
Finally, we asked whether any of these recurrent
aberrations were mutually exclusive in the TCGA
cohort. Any two of the recurrent copy number gains
or losses occurred together within single biopsies
(Figure 4C). Thus, none of these putative driver
aberrations appears to restrict evolutionary possibilities
of ccRCC subclones in terms of further acquisition of
additional recurrent copy number events.
Discussion
Genomic assays are increasingly used for prognostic
or predictive purposes to identify patients at high risk
of recurrence for treatment stratification or to identify
patient cohorts that may be preferentially treated with
specific targeted approaches. Accumulating evidence
suggests that intratumour heterogeneity impacts upon
disease outcome [19,21], therapeutic response [23,37]
and biomarker analysis [15].
Understanding the scale of genetic ITH and its
impact on personalized medicine approaches, patient
outcome and therapeutic resistance is of major clinical
importance. Here, we extend our recent work in
ccRCCs, where we characterized ITH by examining
different biopsies from the same tumour [15]. We now
examined DNA copy number characteristics derived
from multiple tumour regions from each of eight
patients and their relationships to single tumour sam-
ples derived from 440 ccRCCs from TCGA. Our data
indicate that copy number aberrations are likely to
contribute to both inter- and intratumour heterogene-
ity in ccRCCs and reveal that different tumour biop-
sies from the same patient may cluster more closely
 2013 The Authors. Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2013; 230: 356–364
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with other tumours. Our findings further suggest that,
in late stage renal cancer, the extent of intratumour
copy number heterogeneity may closely resemble the
differences observed across large panels of individual
tumours. These results may have relevance across other
tumour types; in particular, Teixeira and colleagues
have previously reported similar observations in pri-
mary breast cancer tumours [38].
These data support a parallel progression model in
which subclones in individual tumours acquire diverse
copy number profiles early after the loss of the p arm
of chromosome 3. Parallel subclone progression may
then lead to subclonal driver aberrations that contribute
to intratumour heterogeneity and tumour sampling
bias. Similarly to evidence of subclonal mutations
impacting upon drug treatment and survival [39],
one or more of these subclonal copy number events
may contribute to tumour progression. Chromosome
9p deletion, for instance, has been associated with
worse prognosis and higher risk of disease recurrence
[40]. In our study, 9p alterations are present as het-
erogeneous copy number aberrations in two of eight
multi-region sampled tumours. Intratumour diversity,
where biopsies from the same tumour may resemble
other tumours more than the tumour from which
they were derived, illustrates the scale of the genetic
dynamics within a single tumour mass. The identifica-
tion of recurrent ubiquitous genetic events, which are
always located in the tumour ’trunk’, and of functional
dependencies and clinical characteristics associated
with such events, may serve to mitigate the challenge
of tumour sampling bias in ccRCCs and provide more
robust targets for therapeutic intervention.
Consistent with our previous demonstration that
good and poor prognostic gene expression signatures
can co-exist within individual ccRCCs [15], this anal-
ysis indicates that the diversity amongst individual
primary ccRCCs may complicate the development of
copy number-based biomarkers and their therapeu-
tic application. Further studies are required to assess
whether the predictive power of genetic tests can be
increased by multi-region assessment. The develop-
ment of non-invasive methods to comprehensively pro-
file the genetics of heterogeneous tumours, for instance
exploiting circulating tumour DNA, may provide a
further step towards understanding the clinical implica-
tions of intratumour heterogeneity and help to resolve
genetic diversity present within individual tumours.
Such techniques would allow the dynamics of sub-
clonal events to be profiled within tumours at multiple
time points during the disease course in order to eluci-
date the contribution of these copy number aberrations
to tumour evolution.
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